Tech Center 1700 • Art Units: 1600 1633 1635 1637 1655 1674 1759
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18260166 | BIOLOGICALLY STABLE XNAZYME THAT EFFICIENTLY SILENCES GENE EXPRESSION IN CELLS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17629512 | ANTIOXIDANT AND ANTIVIRAL COMPOSITIONS AND METHODS | Final Rejection | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17409158 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18255151 | PLASMID FOR TRANSFORMATION, METHOD FOR PRODUCING TRANSFORMANT USING THE SAME, AND TRANSFORMATION METHOD | Non-Final OA | TOYOTA JIDOSHA KABUSHIKI KAISHA |
| 18014977 | COMPOUNDS FOR USE IN THE TREATMENT OF EPILEPSY | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18559078 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY AND COMBINATIONS THEREOF | Non-Final OA | REGENXBIO INC. |
| 18551128 | CELL CULTURE MEDIUM COMPOSITION CONTAINING SPIRULINA HYDROLYSATE, AND PREPARATION METHOD THEREFOR | Non-Final OA | Korea Institute of Ocean Science & Technology |
| 17881335 | DEPLETION PROBES | Final Rejection | Watchmaker Genomics, Inc. |
| 17778463 | VACCINIA VIRUSES AND METHODS FOR USING VACCINIA VIRUSES | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17799418 | TAZ GENE OR ENZYME REPLACEMENT THERAPY | Final Rejection | Children's Medical Center Corporation |
| 18024359 | ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF | Final Rejection | University of Massachusetts |
| 17997264 | Precision Dosing Regimen | Final Rejection | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 17800286 | FUNCTIONALIZED BIOLOGICAL MATRIX MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | VENUS MEDTECH (HANGZHOU) INC. |
| 17999588 | AUGMENTATION OF FIBROBLAST CELL THERAPY EFFICACY BY MICROBIOME MANIPULATION | Non-Final OA | FIGENE, LLC |
| 17594651 | CRISPR/CAS9 GENE EDITING OF ATXN2 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 2 | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18551261 | RECOMBINANT CHIMERIC ADENOVIRAL VECTOR SUBSTITUTED BY KNOB GENE OF CHIMPANZEE ADENOVIRUS SEROTYPE 6, AND APPLICATION THEREOF | Non-Final OA | GENEMATRIX, INC. |
| 17918069 | CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9 | Non-Final OA | Verve Therapeutics, Inc. |
| 18281642 | ANTISENSE OLIGONUCLEOTIDES FOR THEIR USE IN AN ANTI-CANCER TREATMENT | Non-Final OA | CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE |
| 18304394 | FATS AS A TARGET FOR TREATING TUMORS AND USES THEREOF | Non-Final OA | TIANJIN MEDICAL UNIVERSITY |
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | Non-Final OA | Capricor, Inc. |
| 17904984 | TREATMENT OF LIVER FAILURE | Final Rejection | HEPYX LIMITED |
| 17779793 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF | Final Rejection | Chengdu Kanghong Biotechnology Co. Ltd. |
| 17632288 | Poultry Egg-Based Culture Medium | Non-Final OA | SHENZHEN MYTANG BIOTECHNOLOGY CO., LTD. |
| 17280794 | USE OF EXTRACELLULAR VESICLES IN COMBINATION WITH TISSUE PLASMINOGEN ACTIVATOR AND/OR THROMBECTOMY TO TREAT STROKE | Final Rejection | Henry Ford Health System |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy